Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14058092 | 0.82 | CYP2D6 (0.36) | OPRK1HSD17B10SIGMAR1SMN1; SMN2TSHR | |
| SCHEMBL17886562 | 0.82 | TRPV1 (0.36) | OPRK1HSD17B10OPRM1SLC18A3SIGMAR1 | |
| SCHEMBL21078095 | 0.81 | HSD17B10 (0.37) | HSD17B10OPRM1SLC18A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL21788683 | 0.81 | TRPV1 (0.37) | OPRK1HSD17B10OPRM1SLC18A3SIGMAR1 | |
| SCHEMBL8202443 | 0.80 | TRPV1 (0.49) | CACNA1HHSD17B10SMN1; SMN2TSHRTRPV1 | |
| SCHEMBL24621328 | 0.76 | TSHR (0.40) | HSD17B10OPRM1SLC18A3SIGMAR1TSHR | |
| SCHEMBL7358327 | 0.72 | HSD11B1 (0.53) | OPRK1SMN1; SMN2TSHRHTTBRD4 | |
| SCHEMBL8212506 | 0.72 | ALDH1A1 (0.43) | HSD17B10HTTTRPV1 | |
| SCHEMBL8218899 | 0.72 | GPR119 (0.48) | CACNA1HTSHRTRPV1 | |
| SCHEMBL14058463 | 0.72 | BRD4 (0.36) | OPRM1TSHRBRD4USP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | OPRK1 697/4885CACNA1H 578/4885HSD17B10 3307/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | OPRK1 697/4885CACNA1H 578/4885HSD17B10 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.